omniture
logo
Search
CORESTEMCHEMON
Media Room

Latest News

rss

Neuronata-R retains conditional approval in South Korea

South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in M...

2026-07-20 07:00 2139

CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion

SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480)is entering a crit...

2025-12-18 10:31 2673

Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precisi...

2025-09-18 10:28 2821
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for hi...

2025-07-21 10:54 2485

Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potent...

2025-05-29 20:00 3071
Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval